MX2020012065A - Compuestos de ciclopentano. - Google Patents

Compuestos de ciclopentano.

Info

Publication number
MX2020012065A
MX2020012065A MX2020012065A MX2020012065A MX2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A
Authority
MX
Mexico
Prior art keywords
cyclopentane compounds
cyclopentane
compounds
medicine
processes
Prior art date
Application number
MX2020012065A
Other languages
English (en)
Inventor
Grigorios Nikitidis
Xiaolin Zhang
Weitao Pan
Jenny Susanna Marika Lindhagen
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2020012065A publication Critical patent/MX2020012065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de ciclopentano de Fórmula (I), formas físicas de los mismos, procesos para su producción y su uso en medicina. (ver Fórmula).
MX2020012065A 2018-05-11 2019-05-09 Compuestos de ciclopentano. MX2020012065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018086503 2018-05-11
PCT/EP2019/061888 WO2019215268A1 (en) 2018-05-11 2019-05-09 Cyclopentane compounds

Publications (1)

Publication Number Publication Date
MX2020012065A true MX2020012065A (es) 2021-02-26

Family

ID=66542241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012065A MX2020012065A (es) 2018-05-11 2019-05-09 Compuestos de ciclopentano.

Country Status (16)

Country Link
US (2) US11274091B2 (es)
EP (1) EP3790870B1 (es)
JP (1) JP7418354B2 (es)
KR (1) KR20210018287A (es)
CN (1) CN112424182B (es)
AR (1) AR115382A1 (es)
AU (1) AU2019266525A1 (es)
BR (1) BR112020023065A2 (es)
CA (1) CA3099507A1 (es)
DK (1) DK3790870T3 (es)
ES (1) ES2944735T3 (es)
MX (1) MX2020012065A (es)
PT (1) PT3790870T (es)
TW (1) TWI830733B (es)
UY (1) UY38229A (es)
WO (1) WO2019215268A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021079962A1 (ja) * 2019-10-24 2021-04-29 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004017930A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
RU2481336C2 (ru) * 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
JP5512545B2 (ja) * 2008-01-09 2014-06-04 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としてのピリミジルシクロペンタン類
WO2010061329A1 (en) * 2008-11-26 2010-06-03 Pfizer Inc. 3-aminocyclopentanecarboxamides as chemokine receptor modulators
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
CN105308040B (zh) * 2013-06-21 2019-06-04 默克专利股份公司 1,3-二氨基环戊烷甲酰胺衍生物
SG11201600726QA (en) * 2013-07-29 2016-03-30 Merck Patent Gmbh 1,3-disubstituted cyclopentane derivatives

Also Published As

Publication number Publication date
US20210070733A1 (en) 2021-03-11
EP3790870A1 (en) 2021-03-17
TWI830733B (zh) 2024-02-01
JP7418354B2 (ja) 2024-01-19
US20220194922A1 (en) 2022-06-23
BR112020023065A2 (pt) 2021-02-02
DK3790870T3 (da) 2023-05-08
US11274091B2 (en) 2022-03-15
TW202016087A (zh) 2020-05-01
UY38229A (es) 2019-11-29
ES2944735T3 (es) 2023-06-23
KR20210018287A (ko) 2021-02-17
PT3790870T (pt) 2023-05-05
CN112424182A (zh) 2021-02-26
WO2019215268A1 (en) 2019-11-14
EP3790870B1 (en) 2023-04-19
AU2019266525A1 (en) 2020-11-26
CA3099507A1 (en) 2019-11-14
JP2021523178A (ja) 2021-09-02
CN112424182B (zh) 2023-05-23
AR115382A1 (es) 2021-01-13

Similar Documents

Publication Publication Date Title
PH12017501921A1 (en) Novel compounds
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
SA518391864B1 (ar) مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2019015744A (es) Composiciones farmaceuticas.
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
MX2017014035A (es) Formas solidas novedosas.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
CR20200154A (es) Enantiómeros de tiazoles sustituidos como compuestos antivirales
MX2017007377A (es) Compuestos organicos.
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
IN2014MU00916A (es)
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
IN2014CH00304A (es)
EA201790321A1 (ru) Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими
MX2020012065A (es) Compuestos de ciclopentano.
MX2017007380A (es) Compuestos organicos.